Clinical Trials Directory

Trials / Completed

CompletedNCT06101160

Botulinum Toxin Injection for Sialorrhea in Cerebral Palsy

Long-term Follow-up of Safety and Efficacy of OnabotulinumtoxinA for Treatment of Sialorrhea in Juvenile Cerebral Palsy

Status
Completed
Phase
Study type
Observational
Enrollment
61 (actual)
Sponsor
Cairo University · Academic / Other
Sex
All
Age
4 Years – 12 Years
Healthy volunteers

Summary

A 100 units of botulinum toxin was injected in both parotid and submandibular glands for children (2 - 12 years) with incapacitating sialorrhea in juvenile cerebral palsy patients and they are followed up for 1 year

Detailed description

This was a prospective, longitudinal analysis with 1-year follow-up of 52 children with juvenile cerebral palsy (JCP) suffering from sialorrhea enrolled from 3 tertiary pediatric neurology rehabilitation centers (two in Cairo and one in Alexandria) and subjected to repeated BoNT-A injection. The recruitment period was between June 30, 2021, until May 1, 2022 (the last patient follow-up ended on April 30, 2023). Intervention: 100 units of OnabotulinumtoxinA (Botox®) were injected in the parotid and submandibular glands Follow-up visits: mo 1 post-injection (for every injection session) and every 3 months thereafter In each visit; the following efficacy variables were assessed: Primary outcome measures: The severity and frequency of sialorrhea evaluated by Drooling Severity Scale (DSS), and Drooling Frequency Scale (DFS) and visual-analogic ratings of familial distress (VAS-FD). Secondary outcome measure: The carers' Global Impression of Change Scale score measured on a 7-point Likert scale from -3 (very much worse) to +3 (very much improved) Also, adverse events were assessed in each visit

Conditions

Interventions

TypeNameDescription
DRUGonaBoNT-Ainjection under ultrasonography

Timeline

Start date
2021-06-30
Primary completion
2022-05-01
Completion
2023-04-30
First posted
2023-10-26
Last updated
2023-10-27

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06101160. Inclusion in this directory is not an endorsement.